
Unlocking longevity through in-situ Hematopoietic Stem Cell Rejuvenation using combined modulation of aging-disrupted pathways identified by publicly available and proprietary single-cell datasets from young and old human populations. Stem-cell exhaustion is a key hallmark of aging, contributing to impaired tissue repair, immune dysfunction, and systemic frailty. In this project, we took a novel approach to this challenge—rather than replacing aged blood-forming stem cells (HSCs) through transplantation, the project seeks to rejuvenate the body’s own stem cells in situ. We have analysed nearly 850,000 single-cell transcriptomes from healthy donors aged 23 to 91 from publically available and proprietary datasets, generating a high-resolution atlas of hematopoietic aging. The data reveal consistent age-related molecular signatures: younger HSCs show elevated expression of DNA repair and mitochondrial genes, while older cells exhibit ferroptosis drivers, inflammatory signaling (notably TNF and IL-17), and upregulation of CCR9 and long non-coding RNAs. These findings were confirmed in both circulating and bone marrow-derived HSCs, reinforcing their potential as biomarkers and intervention targets. In conclusion, we have identified a list of target genes, which can be used as a intervention for hematopoietic stem cell rejuvenation studies. The key insight is that we are targeting multiple aging mechanisms simultaneously - transcriptional stress responses, epigenetic regulation, and protein homeostasis. Classic damage repair thinking applied to the molecular level. This multi-pronged approach could achieve the robust rejuvenation that single interventions miss.
Unlocking longevity through in-situ Hematopoietic Stem Cell Rejuvenation using combined modulation of aging-disrupted pathways identified by publicly available and proprietary single-cell datasets from young and old human populations.
Stem-cell exhaustion is a key hallmark of aging, contributing to impaired tissue repair, immune dysfunction, and systemic frailty. In this project, we took a novel approach to this challenge—rather than replacing aged blood-forming stem cells (HSCs) through transplantation, the project seeks to rejuvenate the body’s own stem cells in situ. We have analysed nearly 850,000 single-cell transcriptomes from healthy donors aged 23 to 91 from publically available and proprietary datasets, generating a high-resolution atlas of hematopoietic aging. The data reveal consistent age-related molecular signatures: younger HSCs show elevated expression of DNA repair and mitochondrial genes, while older cells exhibit ferroptosis drivers, inflammatory signaling (notably TNF and IL-17), and upregulation of CCR9 and long non-coding RNAs. These findings were confirmed in both circulating and bone marrow-derived HSCs, reinforcing their potential as biomarkers and intervention targets. In conclusion, we have identified a list of target genes, which can be used as a intervention for hematopoietic stem cell rejuvenation studies. The key insight is that we are targeting multiple aging mechanisms simultaneously - transcriptional stress responses, epigenetic regulation, and protein homeostasis. Classic damage repair thinking applied to the molecular level. This multi-pronged approach could achieve the robust rejuvenation that single interventions miss.
Owner
Owner
Owner
Owner
Owner
Owner
Therapeutic Relevance
The proposed mechanism is scientifically plausible and well-grounded. HSC aging is a biologically validated driver of immune decline, anemia, and hematologic malignancies. The project leverages robust single-cell transcriptomic analysis (~850,000 transcriptomes across ages 23–91) to identify differentially expressed genes with very high statistical significance. The targets (e.g., CD38, NR4A1/2, UHRF1, CCR9) are biologically relevant and align with known aging pathways (NAD+ metabolism, epigenetic drift, inflammatory signaling, myeloid skewing). The multi-modal intervention concept—targeting transcriptional stress responses, epigenetic regulation, and protein homeostasis simultaneously—is scientifically rational. However, the score is held back from a 5 because all evidence is computational/bioinformatics-derived with no experimental validation yet, the AubrAI-generated hypothesis adds speculative complexity, and the sheer number of targets and intervention modalities raises questions about focus and feasibility at this early stage.
Therapeutic Optionality
The mechanism demonstrates strong therapeutic optionality. HSC rejuvenation could address multiple therapeutic areas: age-related immune decline (immunosenescence), anemia, susceptibility to infections, myelodysplastic syndromes, leukemia prevention, and broader healthy aging/frailty. The multi-modal approach (mRNA, siRNA, small molecules, CRISPR, gene therapy, nanoparticle delivery) provides flexibility in intervention modality. The concept is inherently flexible—individual validated targets could be pursued independently or in combination, and the platform (scRNA-seq + AI/ML target identification) could be applied to other stem cell types beyond HSCs. The score is not a 5 because the optionality remains theoretical at this stage, and the breadth of proposed applications may exceed what can realistically be validated with the current resources and timeline.
Intellectual Property
The concept has moderate novelty for patenting. The specific combination of targets identified through their proprietary scRNA-seq analysis pipeline and the multi-modal intervention strategy could be patentable, particularly the specific gene combinations and temporal coordination protocol for HSC rejuvenation. However, several concerns limit the IP score: (1) No patents have been filed or granted yet—IP advancement is only listed as a future project outcome. (2) Many individual targets (CD38, RhoA, mTOR/rapamycin, NR4A family) are well-known in the aging and hematopoiesis literature, creating significant prior art risk. (3) The proposed small molecules (Fasudil, rapamycin, cromolyn sodium) are existing drugs, limiting composition-of-matter claims. (4) The computational analysis relies partly on publicly available datasets, which could weaken novelty claims. (5) The competitive landscape in HSC rejuvenation and aging therapeutics is active. Potential IP strength lies in the specific combination/cocktail approach and any proprietary datasets or pipeline innovations, but this remains unprotected and unvalidated.